5-Year Overall Survival in COLUMBUS: a randomized Phase 3 Study of Encorafenib plus Binimetinib versus Vemurafenib or Encorafenib in Patients with BRAFV600-mutated Melanoma
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT(2021)
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined